The main purpose of this legislation is to establish stricter regulations around the use of mifepristone, a medication commonly used for medical abortions. The law aims to reinstate a previous risk evaluation and mitigation strategy that was in place for this drug, which is intended to ensure its safe use and to address concerns about potential risks associated with it. Key provisions of the law require the Secretary of Health and Human Services to withdraw the current risk evaluation and mitigation strategy for mifepristone and replace it with the one that was approved in June 2011.